Review: In type 2 diabetes, SGLT-2 inhibitors or GLP-1 agonists reduce mortality vs control or DPP-4 inhibitors

Aoife M. Egan, Victor M. Montori

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Pages (from-to)JC2
JournalAnnals of internal medicine
Volume169
Issue number2
DOIs
StatePublished - Jul 17 2018

Fingerprint

Dipeptidyl-Peptidase IV Inhibitors
Glucagon-Like Peptide 1
Hypoglycemic Agents
Type 2 Diabetes Mellitus
Sodium
Glucose
Mortality

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Review : In type 2 diabetes, SGLT-2 inhibitors or GLP-1 agonists reduce mortality vs control or DPP-4 inhibitors. / Egan, Aoife M.; Montori, Victor M.

In: Annals of internal medicine, Vol. 169, No. 2, 17.07.2018, p. JC2.

Research output: Contribution to journalComment/debate

@article{b30ee3985a9a4c16a39e797dfdece153,
title = "Review: In type 2 diabetes, SGLT-2 inhibitors or GLP-1 agonists reduce mortality vs control or DPP-4 inhibitors",
author = "Egan, {Aoife M.} and Montori, {Victor M.}",
year = "2018",
month = "7",
day = "17",
doi = "10.7326/ACPJC-2018-169-2-002",
language = "English (US)",
volume = "169",
pages = "JC2",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "2",

}

TY - JOUR

T1 - Review

T2 - In type 2 diabetes, SGLT-2 inhibitors or GLP-1 agonists reduce mortality vs control or DPP-4 inhibitors

AU - Egan, Aoife M.

AU - Montori, Victor M.

PY - 2018/7/17

Y1 - 2018/7/17

UR - http://www.scopus.com/inward/record.url?scp=85071355324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071355324&partnerID=8YFLogxK

U2 - 10.7326/ACPJC-2018-169-2-002

DO - 10.7326/ACPJC-2018-169-2-002

M3 - Comment/debate

C2 - 30014091

AN - SCOPUS:85071355324

VL - 169

SP - JC2

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 2

ER -